Guggenheim initiated coverage of Oculis (OCS) with a Buy rating and $75 price target The firm sees OCS-01 having the potential to become the first non-invasive topical treatment for DME, which it calls a large market with about 1M immediately addressable patients currently underserved by injection-based therapies.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS:
- Oculis price target raised to $42 from $38 at JPMorgan
- Oculis AGM Backs All Proposals, Adds Veteran Biotech CFO to Board and Expands Capital Flexibility
- Oculis price target raised to $47 from $44 at H.C. Wainwright
- Oculis price target raised to $44 from $43 at BofA
- Oculis reports Q1 EPS (49c), consensus (41c)